In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets

The administration of Everolimus (EVE), a mTOR inhibitor used in transplantation and cancer, is often associated with adverse effects including pulmonary fibrosis. Although the underlying mechanism is not fully clarified, this condition could be in part caused by epithelial to mesenchymal transition...

Descripción completa

Detalles Bibliográficos
Autores principales: Granata, Simona, Santoro, Gloria, Masola, Valentina, Tomei, Paola, Sallustio, Fabio, Pontrelli, Paola, Accetturo, Matteo, Antonucci, Nadia, Carratù, Pierluigi, Lupo, Antonio, Zaza, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979287/
https://www.ncbi.nlm.nih.gov/pubmed/29677166
http://dx.doi.org/10.3390/ijms19041250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979287/
https://www.ncbi.nlm.nih.gov/pubmed/29677166
http://dx.doi.org/10.3390/ijms19041250

Ejemplares similares